Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mestan

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Medicinal Chemistry|August 2, 1996
Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailabilityA Fässler, G Bold, H G Capraro, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 21, 2001
Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitroJ C Tille, J Wood, S J Mandriota, et al.
Archiv Der Pharmazie|June 1, 1996
Synthesis of potent and orally active HIV-protease inhibitorsH G Capraro, G Bold, A Fässler, et al.
Schweizerische Medizinische Wochenschrift|October 26, 1996
Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitroJ K Lazdins, G Bold, H G Capraro, et al.
Journal of Medicinal Chemistry|August 28, 1998
New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical developmentG Bold, A Fässler, H G Capraro, et al.
Journal of Medicinal Chemistry|July 6, 2000
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesisG Bold, K H Altmann, J Frei, et al.
Cancer Research|April 29, 2000
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationJ M Wood, G Bold, E Buchdunger, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Medicinal Chemistry|August 2, 1996
Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailabilityA Fässler, G Bold, H G Capraro, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 21, 2001
Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitroJ C Tille, J Wood, S J Mandriota, et al.
Archiv Der Pharmazie|June 1, 1996
Synthesis of potent and orally active HIV-protease inhibitorsH G Capraro, G Bold, A Fässler, et al.
Schweizerische Medizinische Wochenschrift|October 26, 1996
Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitroJ K Lazdins, G Bold, H G Capraro, et al.
Journal of Medicinal Chemistry|August 28, 1998
New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical developmentG Bold, A Fässler, H G Capraro, et al.
Journal of Medicinal Chemistry|July 6, 2000
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesisG Bold, K H Altmann, J Frei, et al.
Cancer Research|April 29, 2000
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationJ M Wood, G Bold, E Buchdunger, et al.
Pageof 3